Tag Archives: Sorrento Therapeutics

November, 2018

7 November
Sorrento’s Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity with Increased Overall Survival in Pancreatic Cancer Patients with Liver Metastases

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for …
Share

3 March
Sorrento Therapeutics and Yuhan Form Joint Venture Company ImmuneOncia

SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation (000100.KS; Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced …
Share